Krebs Biochemicals & Industries Limited (KREBSBIO.NS)
INR 73.54
(1.56%)
INR 73.54
(1.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.97 Billion INR | 8.36% |
| 2022 | 2.74 Billion INR | 3.6% |
| 2021 | 2.64 Billion INR | 31.17% |
| 2020 | 2.01 Billion INR | 27.18% |
| 2019 | 1.58 Billion INR | 1.37% |
| 2018 | 1.56 Billion INR | 9.05% |
| 2017 | 1.43 Billion INR | 19.12% |
| 2016 | 1.2 Billion INR | 16.63% |
| 2015 | 1.03 Billion INR | 14.69% |
| 2014 | 901.62 Million INR | 0.0% |
| 2012 | 1.29 Billion INR | 3.38% |
| 2011 | 1.25 Billion INR | 7.92% |
| 2010 | 1.16 Billion INR | 3.93% |
| 2009 | 1.11 Billion INR | -6.81% |
| 2008 | 1.19 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.19 Billion INR | -59.91% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 2.97 Billion INR | 8.36% |
| 2023 Q2 | 2.86 Billion INR | 0.0% |
| 2023 Q4 | 2.97 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 2.74 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 2.74 Billion INR | 3.6% |
| 2022 Q2 | 2.7 Billion INR | 0.0% |
| 2021 Q4 | 2.64 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.64 Billion INR | 31.17% |
| 2021 Q2 | 2.24 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 2.01 Billion INR | 27.18% |
| 2020 Q2 | 1.78 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 2.01 Billion INR | 0.0% |
| 2019 Q4 | 1.58 Billion INR | 0.0% |
| 2019 FY | 1.58 Billion INR | 1.37% |
| 2019 Q2 | 1.6 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q2 | 1.49 Billion INR | 4.78% |
| 2018 Q1 | 1.43 Billion INR | -0.38% |
| 2018 FY | 1.56 Billion INR | 9.05% |
| 2018 Q4 | 1.56 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.33 Billion INR | 0.0% |
| 2017 Q4 | 1.43 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 1.43 Billion INR | 19.12% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q4 | 1.2 Billion INR | 0.0% |
| 2016 FY | 1.2 Billion INR | 16.63% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 1.12 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 1.03 Billion INR | 14.69% |
| 2015 Q4 | 1.03 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 957.63 Million INR | 0.0% |
| 2014 Q4 | 901.62 Million INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2014 FY | 901.62 Million INR | 0.0% |
| 2013 Q2 | 1.29 Billion INR | 0.0% |
| 2013 Q4 | - INR | -100.0% |
| 2013 Q3 | 1.33 Billion INR | 3.31% |
| 2012 FY | 1.29 Billion INR | 3.38% |
| 2012 Q2 | 1.29 Billion INR | 0.0% |
| 2011 Q4 | 1.25 Billion INR | 0.0% |
| 2011 FY | 1.25 Billion INR | 7.92% |
| 2010 FY | 1.16 Billion INR | 3.93% |
| 2009 FY | 1.11 Billion INR | -6.81% |
| 2008 FY | 1.19 Billion INR | 0.0% |
| 2008 Q4 | 1.19 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 81.726% |
| Hester Biosciences Limited | 3.59 Billion INR | 17.27% |
| Aarti Drugs Limited | 11.5 Billion INR | 74.149% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 63.956% |
| Albert David Limited | 1.15 Billion INR | -158.578% |
| Alembic Limited | 1.43 Billion INR | -107.661% |
| Alkem Laboratories Limited | 48.6 Billion INR | 93.881% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -355.927% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 38.905% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -929.752% |
| Brooks Laboratories Limited | 248.6 Million INR | -1096.26% |
| Eris Lifesciences Limited | 38.26 Billion INR | 92.229% |
| FDC Limited | 3.7 Billion INR | 19.823% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 42.599% |
| Gufic Biosciences Limited | 5.59 Billion INR | 46.893% |
| Hikal Limited | 12.99 Billion INR | 77.115% |
| Ind-Swift Limited | 13.45 Billion INR | 77.894% |
| Innova Captab Limited | 4.89 Billion INR | 39.306% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 53.011% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -902.128% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 95.147% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -176.76% |
| Lupin Limited | 96.23 Billion INR | 96.91% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -50.478% |
| Medico Remedies Limited | 438.24 Million INR | -578.598% |
| Morepen Laboratories Limited | 4.45 Billion INR | 33.317% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 73.49% |
| Orchid Pharma Limited | 3.84 Billion INR | 22.636% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -16.114% |
| RPG Life Sciences Limited | 1.38 Billion INR | -115.47% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -361.872% |
| Sigachi Industries Limited | 2.53 Billion INR | -17.487% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 78.896% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -46.194% |
| Themis Medicare Limited | 1.88 Billion INR | -57.557% |
| Unichem Laboratories Limited | 8.06 Billion INR | 63.145% |
| Vaishali Pharma Limited | 371.16 Million INR | -701.242% |
| Wanbury Limited | 3.15 Billion INR | 5.755% |
| Windlas Biotech Limited | 1.76 Billion INR | -68.714% |
| ZIM Laboratories Limited | 2.08 Billion INR | -42.924% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -29.896% |
| Ipca Laboratories Limited | 33.74 Billion INR | 91.187% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.38% |
| Venus Remedies Limited | 1.39 Billion INR | -113.521% |
| Sakar Healthcare Limited | 1.26 Billion INR | -135.412% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 98.046% |
| Divi's Laboratories Limited | 18.99 Billion INR | 84.34% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 18.77% |
| Mankind Pharma Limited | 23.87 Billion INR | 87.544% |
| Sequent Scientific Limited | 8.27 Billion INR | 64.058% |
| Laurus Labs Limited | 42.71 Billion INR | 93.038% |
| Neuland Laboratories Limited | 5.49 Billion INR | 45.915% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 72.227% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 95.433% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 95.858% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -279.411% |
| Wockhardt Limited | 39.87 Billion INR | 92.541% |
| Bal Pharma Limited | 2.51 Billion INR | -18.422% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 97.22% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -41.021% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -1761.127% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 15.167% |
| Shilpa Medicare Limited | 12.93 Billion INR | 77.004% |
| Valiant Laboratories Limited | 1.05 Billion INR | -181.019% |
| Ajanta Pharma Limited | 10.71 Billion INR | 72.233% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -72.682% |
| Granules India Limited | 22.95 Billion INR | 87.044% |
| Medicamen Biotech Limited | 940.36 Million INR | -216.25% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -155.225% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.469% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 96.375% |
| NATCO Pharma Limited | 10.53 Billion INR | 71.763% |
| Suven Life Sciences Limited | 148.62 Million INR | -1901.005% |
| Strides Pharma Science Limited | 37.68 Billion INR | 92.108% |
| Indoco Remedies Limited | 10.34 Billion INR | 71.245% |
| Alpa Laboratories Limited | 307.12 Million INR | -868.317% |
| Lasa Supergenerics Limited | 541.92 Million INR | -448.769% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 23.607% |